Evidence map›Paper›PMID 42109180›Full record

ArticleFuture oncology (London, England)2026

Real-world treatment patterns for metastatic urothelial cancer in 5 European countries: EVEREST 2.

Maria De Santis, Neil Milloy, Maria Walley, Amber Simpson, Cameron Forshaw, Marthe Vuillet, Torsten Strunz-McKendry, Janet Kim, Marie-Catherine Thomas

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Future oncology (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Maria De SantisDepartment of Urology, Charité Universitätsmedizin Berlin, Berlin, Germany.
Neil MilloyAdelphi Real World, Bollington, UK.
Maria WalleyAdelphi Real World, Bollington, UK.ORCID 0009-0007-8296-4784
Amber SimpsonAdelphi Real World, Bollington, UK.ORCID 0009-0005-2348-0400
Cameron ForshawAdelphi Real World, Bollington, UK.ORCID 0000-0001-8125-697X
Marthe VuilletAstellas Pharma France, Levallois-Perret, France.
Torsten Strunz-McKendryAstellas Pharma Europe, Addlestone, UK.ORCID 0000-0001-6032-8794
Janet KimAstellas Pharma Inc, Northbrook, IL, USA.
Marie-Catherine ThomasAstellas Pharma France, Levallois-Perret, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionTreatment for locally advanced or metastatic urothelial carcinoma (la/mUC) is evolving in Europe. In 2022, ESMO guidelines recommended avelumab as first-line (1L) maintenance for la/mUC in patients who did not progress on platinum-based chemotherapy (PBC) and, in March 2024, recommended enfortumab vedotin (EV) plus pembrolizumab as the preferred 1L therapy. This study assessed treatment patterns for mUC between December 2023-May 2024.

methodsData were drawn from the Adelphi Real World mUC Disease Specific Programme™, a cross-sectional survey of physician-reported data across France, Germany, Italy, Spain, and the United Kingdom.

resultsPhysicians (

conclusionsConsistent with guidelines, adoption of avelumab maintenance was occurring, although its usage remained limited. Low rates of 2L+ therapies highlight the importance of 1L treatment selection.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsCarcinoma, Transitional CellPractice Patterns, Physicians'Urologic NeoplasmsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedCross-Sectional StudiesEuropeFemaleHumansMaleNeoplasm MetastasisAntibodies, MonoclonalAntibodies, Monoclonal, Humanizedavelumabenfortumab vedotinpembrolizumabAvelumabchemotherapyenfortumab vedotinEuropeimmune checkpoint inhibitorsmaintenance treatmentmetastatic urothelial carcinomareal-world evidence

Identifiers

PMID42109180
PMCPMC13203028

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.